Eyeworld

67 EW GLAUCOMA May 2016 Editors' note: Dr. Craven has financial interests with Allergan, Alcon (Fort Worth, Texas), Pfizer (New York), Transcend Medical (Menlo Park, Cali- fornia), and Ivantis (Irvine, California). liposomal latanoprost was well toler- ated by the 6 subjects and produced a mean IOP decrease of 13.03 mm Hg (about 47%) from the baseline of 27.55 mm Hg. Both a clinically and statistically significant IOP reduction held through 3 months. Dr. Quigley is working with colleagues to develop a microparti- cle-encapsulated version of dorzol- amide and other drugs that can be delivered subconjunctivally. With the average glaucoma patient living about 16 years past onset, that could lead to numer- ous injections. "If you're injecting through the cornea 32 times in that 16 years, whatever you're leaving be- hind better be benign," Dr. Quigley said. "There isn't as much 'space' in the anterior chamber and vitreous as there is in the subconjunctiva." In the rabbit studies on the encapsulated dorzolamide, "the sub- conjunctival histology does not sug- gest that there's any remaining par- ticle material there by 90 days. The material is largely being absorbed by macrophages," Dr. Quigley said. One thing is certain—there are numerous new drugs and drug deliv- ery systems being explored. "Maybe it was the science that changed interest levels," Dr. Novack said. "We're fortunate that compa- nies are investing in this area again. It's better for our patients in the long run." EW References 1. Goldberg I, et al. Maintenance of IOP-reduc- tion for 6 months with a single dose of a novel topically applied bimatoprost ocular insert in patients with open-angle glaucoma or ocular hypertension. Poster presented at the 2015 World Glaucoma Congress. 2. Brandt JD, et al. Six-month IOP reduction with a single dose of a novel topical bimato- prost ocular insert: A phase 2 randomized double-masked, controlled study. Paper presented at the 2015 American Academy of Ophthalmology meeting. 3. Wong TT, Novack GD, et al. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substan- tial benefits over eyedrops. Drug Deliv Transl Res. 2014;4:303–9. Dr. Quigley has financial interests with GrayBug, Alcon, Allergan, and Genentech (South San Francisco). Dr. Novack has no financial interests related to this article. Contact information Craven: ecraven1@jhmi.edu Novack: gary_novack@pharmalogic.com Quigley: hquigley@jhmi.edu

• Cover